Ron AlfainRecursionArtificial Intelligence Provides a Beacon to New Medicine for Neurofibromatosis type 2Recursion Signs Global Licensing Agreement with the Ohio State Innovation Foundation to Develop REC-2282 to Treat Neurofibromatosis Type 2Jan 4, 2019Jan 4, 2019